Symbols

CGEN

Compugen·NASDAQ

--(--)

CGEN fundamentals

CGEN Q4 2025 Earnings

Compugen (CGEN) released its earnings on Mar 2, 2026: revenue was 67.33M (YoY +4477.29%), beat estimates; EPS was 0.6 (YoY +957.14%), beat estimates.

Revenue / YoY

67.33M

+4477.29%

EPS / YoY

0.6

+957.14%

Report date

Mar 2, 2026

CGEN Earnings Call Summary for Q4,2025

$65M AstraZeneca Deal: Extended cash runway to 2029, with $195M in remaining milestones and retained royalties on $5B+ potential Rilve sales.
Clinical Catalysts: COM701 interim analysis in Q1 2027; GS-0321 Phase I trial ongoing with $758M in potential milestones.
Financial Strength: 2025 revenue of $72.8M, net profit of $35.3M, and $145.6M cash as of Q4 2025.
Strategic Partnerships: Gilead and AstraZeneca collaborations driving pipeline value, with AstraZeneca expanding Rilve trials to 11 Phase III.

Earnings

EPS

Revenue

Revenue & Expenses

CGEN has released its 2025 Q4 earnings report, with revenue of 67.33M, reflecting a YoY change of 4477.29%, and net profit of 56.84M, showing a YoY change of 1029.30%. The Sankey diagram below clearly presents CGEN's revenue sources and cost distribution.

Key Indicators

Compugen (CGEN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Compugen (CGEN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Compugen (CGEN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Compugen (CGEN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown